Effect of Gemigliptin on Cardiac Ischemia/reperfusion and Spontaneous Hypertensive Rat Models

Overview

Journal Korean J Physiol Pharmacol

Specialty Pharmacology

Date 2019 Sep 10

PMID 31496870

Citations 2

Authors

Dae-Hwan Nam

Jinsook Park

Sun-Hyun Park

Ki-Suk Kim

Eun Bok Baek

Affiliations

Soon will be listed here.

Abstract

Diabetes is associated with an increased risk of cardiovascular complications. Dipeptidyl peptidase-4 (DPP-IV) inhibitors are used clinically to reduce high blood glucose levels as an antidiabetic agent. However, the effect of the DPP-IV inhibitor gemigliptin on ischemia/reperfusion (I/R)-induced myocardial injury and hypertension is unknown. In this study, we assessed the effects and mechanisms of gemigliptin in rat models of myocardial I/R injury and spontaneous hypertension. Gemigliptin (20 and 100 mg/kg/d) or vehicle was administered intragastrically to Sprague-Dawley rats for 4 weeks before induction of I/R injury. Gemigliptin exerted a preventive effect on I/R injury by improving hemodynamic function and reducing infarct size compared to the vehicle control group. Moreover, administration of gemigliptin (0.03% and 0.15%) powder in food for 4 weeks reversed hypertrophy and improved diastolic function in spontaneously hypertensive rats. We report here a novel effect of the gemigliptin on I/R injury and hypertension.

Citing Articles

Sitagliptin Modulates Oxidative, Nitrative and Halogenative Stress and Inflammatory Response in Rat Model of Hepatic Ischemia-Reperfusion.

Trocha M, Fleszar M, Fortuna P, Lewandowski L, Gostomska-Pampuch K, Sozanski T Antioxidants (Basel). 2021; 10(8).

PMID: 34439416 PMC: 8388898. DOI: 10.3390/antiox10081168.

Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity.

Tavares C, Bailey M, Girardi A Front Physiol. 2020; 11:599729.

PMID: 33329052 PMC: 7710931. DOI: 10.3389/fphys.2020.599729.

References

Lambeir A, Durinx C, Scharpe S, De Meester I . Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003; 40(3):209-94. DOI: 10.1080/713609354. View

Daousi C, Casson I, Gill G, MacFarlane I, Wilding J, Pinkney J . Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006; 82(966):280-4. PMC: 2579635. DOI: 10.1136/pmj.2005.039032. View

Ahren B . Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007; 30(6):1344-50. DOI: 10.2337/dc07-0233. View

Lim K, Kim J, Choi Y, Shin K, Kim K, Hong J . Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin Ther. 2008; 30(10):1817-30. DOI: 10.1016/j.clinthera.2008.10.013. View

Sauve M, Ban K, Momen M, Zhou Y, Henkelman R, Husain M . Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010; 59(4):1063-73. PMC: 2844815. DOI: 10.2337/db09-0955. View

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

Fadini G, Avogaro A . Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011; 55(1-3):10-6. DOI: 10.1016/j.vph.2011.05.001. View

Ku H, Chen W, Su M . DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol. 2011; 384(2):197-207. DOI: 10.1007/s00210-011-0665-3. View

Liu L, Liu J, Wong W, Tian X, Lau C, Wang Y . Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012; 60(3):833-41. DOI: 10.1161/HYPERTENSIONAHA.112.195115. View

10.

Giannocco G, Oliveira K, Crajoinas R, Venturini G, Salles T, Fonseca-Alaniz M . Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol. 2012; 698(1-3):74-86. DOI: 10.1016/j.ejphar.2012.09.043. View

11.

Lee T, Kao Y, Chen Y, Huang J, Hsu M, Chen Y . The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int J Cardiol. 2013; 168(6):5390-5. DOI: 10.1016/j.ijcard.2013.08.051. View

12.

Hausenloy D, Whittington H, Wynne A, Begum S, Theodorou L, Riksen N . Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol. 2013; 12:154. PMC: 3815626. DOI: 10.1186/1475-2840-12-154. View

13.

Powers S, Smuder A, Kavazis A, Quindry J . Mechanisms of exercise-induced cardioprotection. Physiology (Bethesda). 2014; 29(1):27-38. PMC: 3929117. DOI: 10.1152/physiol.00030.2013. View

14.

Dardano A, Penno G, Del Prato S, Miccoli R . Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY). 2014; 6(3):187-206. PMC: 4012936. DOI: 10.18632/aging.100646. View

15.

Martin-Timon I, Sevillano-Collantes C, Segura-Galindo A, Del Canizo-Gomez F . Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?. World J Diabetes. 2014; 5(4):444-70. PMC: 4127581. DOI: 10.4239/wjd.v5.i4.444. View

16.

Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D . DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol. 2014; 13:157. PMC: 4255443. DOI: 10.1186/s12933-014-0157-0. View

17.

Ihara M, Asanuma H, Yamazaki S, Kato H, Asano Y, Shinozaki Y . An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2015; 308(10):H1287-97. DOI: 10.1152/ajpheart.00835.2014. View

18.

Kim S, Jung E, Yoon M, Kwon O, Hwang D, Kim D . Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016; 788:54-64. DOI: 10.1016/j.ejphar.2016.06.016. View

19.

Kim S, Yoo J, Lee W, Park C . Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J. 2016; 40(5):339-353. PMC: 5069390. DOI: 10.4093/dmj.2016.40.5.339. View

20.

Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda L, Roviezzo F . Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol. 2016; 174(22):4070-4086. PMC: 5659996. DOI: 10.1111/bph.13686. View